Restifo, Nicholas P.
National Cancer Institute (NCI),
United States
2025 Rank: 9809
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 201 out of 166615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 9809 | 11223 |
| Total Cites | 3561 | 3655 |
| H-index | 34 | 34 |
| Hm-index | 11 | 11 |
| Number of Single Authored Papers | 11 | 11 |
| Total Cites to Single Authored Papers | 3 | 3 |
| Number of Single+First Authored Papers | 28 | 28 |
| Total Cites to Single+First Authored Papers | 134 | 134 |
| Number of Single+First+Last Authored Papers | 174 | 174 |
| Total Cites to Single+First+Last Authored Papers | 1855 | 1908 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 2455 | 2478 |
| Ratio of Total Citations to Distinct Citing Papers | 1.45 | 1.47 |
| Self-Citation Percentage |
2.57%
|
|
Restifo, Nicholas P.
National Institutes of Health (NIH),
United States
2024 Rank: 7102
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 168 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 7102 | 8075 |
| Total Cites | 3808 | 3890 |
| H-index | 33 | 34 |
| Hm-index | 12 | 12 |
| Number of Single Authored Papers | 11 | 11 |
| Total Cites to Single Authored Papers | 4 | 4 |
| Number of Single+First Authored Papers | 28 | 28 |
| Total Cites to Single+First Authored Papers | 163 | 163 |
| Number of Single+First+Last Authored Papers | 175 | 175 |
| Total Cites to Single+First+Last Authored Papers | 1958 | 1994 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 2547 | 2572 |
| Ratio of Total Citations to Distinct Citing Papers | 1.50 | 1.51 |
| Self-Citation Percentage |
2.11%
|
|
Restifo, Nicholas P.
National Cancer Institute (NCI),
United States
2023 Rank: 3928
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 100 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 3928 | 4522 |
| Total Cites | 5123 | 5267 |
| H-index | 39 | 39 |
| Hm-index | 14 | 14 |
| Number of Single Authored Papers | 11 | 11 |
| Total Cites to Single Authored Papers | 6 | 6 |
| Number of Single+First Authored Papers | 28 | 28 |
| Total Cites to Single+First Authored Papers | 201 | 203 |
| Number of Single+First+Last Authored Papers | 188 | 188 |
| Total Cites to Single+First+Last Authored Papers | 2442 | 2499 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3239 | 3294 |
| Ratio of Total Citations to Distinct Citing Papers | 1.58 | 1.60 |
| Self-Citation Percentage |
2.73%
|
|
Restifo, Nicholas P.
National Cancer Institute (NCI),
United States
2022 Rank: 3003
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 83 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 3003 | 3316 |
| Total Cites | 5405 | 5580 |
| H-index | 40 | 41 |
| Hm-index | 14 | 14 |
| Number of Single Authored Papers | 11 | 11 |
| Total Cites to Single Authored Papers | 7 | 7 |
| Number of Single+First Authored Papers | 28 | 28 |
| Total Cites to Single+First Authored Papers | 246 | 248 |
| Number of Single+First+Last Authored Papers | 184 | 184 |
| Total Cites to Single+First+Last Authored Papers | 2685 | 2737 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3324 | 3387 |
| Ratio of Total Citations to Distinct Citing Papers | 1.63 | 1.65 |
| Self-Citation Percentage |
3.14%
|
|
Restifo, Nicholas P.
National Cancer Institute (NCI),
United States
2021 Rank: 3673
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 96 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 3673 | 4188 |
| Total Cites | 7772 | 8019 |
| H-index | 48 | 49 |
| Hm-index | 16 | 17 |
| Number of Single Authored Papers | 11 | 11 |
| Total Cites to Single Authored Papers | 8 | 8 |
| Number of Single+First Authored Papers | 28 | 28 |
| Total Cites to Single+First Authored Papers | 359 | 363 |
| Number of Single+First+Last Authored Papers | 183 | 183 |
| Total Cites to Single+First+Last Authored Papers | 3849 | 3940 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4733 | 4810 |
| Ratio of Total Citations to Distinct Citing Papers | 1.64 | 1.67 |
| Self-Citation Percentage |
3.08%
|
|
Restifo, Nicholas P.
National Cancer Institute,
United States
2020 Rank: 3621
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 84 out of 108509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 3621 | 3746 |
| Total Cites | 5450 | 5802 |
| H-index | 40 | 42 |
| Hm-index | 13 | 14 |
| Number of Single Authored Papers | 11 | 11 |
| Total Cites to Single Authored Papers | 10 | 10 |
| Number of Single+First Authored Papers | 28 | 28 |
| Total Cites to Single+First Authored Papers | 258 | 268 |
| Number of Single+First+Last Authored Papers | 181 | 181 |
| Total Cites to Single+First+Last Authored Papers | 2732 | 2893 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3200 | 3281 |
| Ratio of Total Citations to Distinct Citing Papers | 1.70 | 1.77 |
| Self-Citation Percentage |
6.07%
|
|